Skip to main content
NIH funding notice RFA-NS-23-017

Optimization of Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (U01 - Clinical Trials Not Allowed)

Closed on November 30, 2022.

Posted
August 24, 2022
Close date
November 30, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,982,785 in first-year total cost, median $1,491,393.

Most frequent study sections

  1. Special Emphasis Panel[ZNS1 SRB-T (55)]2

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
  2. UNIVERSITY OF CALIFORNIA, SAN FRANCISCO1
Competing awards under RFA-NS-23-017 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Testing Optimal Gene Editor for an Alzheimer's CRISPR therapeutic.1UF1NS134063-01ROY, SUBHOJITUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$2,112,826ZNS1
2023Optimization of CRISPR genome editor and its delivery strategy for C9orf72 frontotemporal dementia1U01NS134062-01CLELLAND, CLAIREGONG, SHAOQIN -UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA$869,959ZNS1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-NS-23-017: Optimization of Genome Editing Therapeutics for Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) (U01 - Clinical Trials Not Allowed) | ScienceDex | ConductScience